The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease?
Abstract
The cardiovascular system is regulated by hemodynamic and neurohumoral mechanisms. These regulatory systems play a key role in modulating cardiac function, vascular tone, and structure. Although neurohumoral systems are essential in vascular homeostasis, they become maladaptive in disease states such as hypertension, coronary disease, and heart failure. The clinical success of ACE inhibitors has led to efforts to block other humoral systems. Neutral endopeptidase (NEP) is an endothelial cell surface zinc metallopeptidase with similar structure and catalytic site. NEP is the major enzymatic pathway for degradation of natriuretic peptides, a secondary enzymatic pathway for degradation of kinins, and adrenomedullin. The natriuretic peptides can be viewed as endogenous inhibitors of the renin angiotensin system. Inhibition of NEP increases levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) of myocardial cell origin, and C-type natriuretic peptide (CNP) of endothelial cell origin as well as bradykinin and adrenomedullin. By simultaneously inhibiting the renin-angiotensin-aldosterone system and potentiating the natriuretic peptide and kinin systems, vasopeptidase inhibitors reduce vasoconstriction, enhance vasodilation, improve sodium/water balance, and, in turn, decrease peripheral vascular resistance and blood pressure and improve local blood flow. Within the blood vessel wall, this leads to a reduction of vasoconstrictor and proliferative mediators such as angiotensin II and increased local levels of bradykinin (and, in turn, nitric oxide) and natriuretic peptides. Preliminary clinical experiences with vasopeptidase inhibitors are encouraging. Thus, the combined inhibition of ACE and neutral endopeptidase is a new and promising approach to treat patients with hypertension, atherosclerosis, or heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
Palmer, R. M. J., Ferrige, A. G., & Moncada, S. (1987) · Nature · doi:10.1038/327524a0 · Cited by 10,704
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Mancini, G. B. J., Henry, G. C., Macaya, C., O'Neill, B. J., Pucillo, A. L., Carere, R. G., Wargovich, T. J., Mudra, H., Lu¨scher, T. F., Klibaner, M. I., et al. (1996) · Circulation · doi:10.1161/01.cir.94.3.258 · Cited by 1,057
Self-citationColucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L. E., Givertz, M. M., Liang, C.-S., Neibaur, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430403 · Cited by 911
Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the Human
Burnett, J. C., Kao, P. C., Hu, D. C., Heser, D. W., Heublein, D., Granger, J. P., Opgenorth, T. J., & Reeder, G. S. (1986) · Science · doi:10.1126/science.2935937 · Cited by 891
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Effects of synthetic atrial natriuretic factor on renal function and renin release
Burnett, J. C. J., Granger, J. P., & Opgenorth, T. J. (1984) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1984.247.5.f863 · Cited by 533
(2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432019 · Cited by 526
Rouleau, J. L., Pfeffer, M. A., Stewart, D. J., Isaac, D., Sestier, F., Kerut, E. K., Porter, C. B., Proulx, G., Qian, C., & Block, A. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02602-7 · Cited by 396
Self-citationWiemer, G., Schölkens, B. A., Becker, R. H., & Busse, R. (1991) · Hypertension · doi:10.1161/01.hyp.18.4.558 · Cited by 349
Cited by
New approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276
Savoia, C., Volpe, M., Alonzo, A., Rossi, C., & Rubattu, S. (2010) · Clinical Science · doi:10.1042/cs20090204 · Cited by 35
Metadata
- Authors
- Corti, R., Burnett Jr, J. C., Rouleau, J. L., Ruschitzka, F., & Lüscher, T. F.
- Venue
- Circulation
- Published
- 2001-10-09
- Volume
- 104
- Issue
- 15
- Pages
- 1856-1862
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2129272798
- Cited by
- 300
- References
- 41
- FWCI
- 18.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? https://app.cochat.ai/papers/10.1161/hc4001.097191
- The paper
- Corti, R., Burnett Jr, J. C., Rouleau, J. L., Ruschitzka, F., & Lüscher, T. F. (2001). Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? Circulation. https://doi.org/10.1161/hc4001.097191
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.